Abstract: A composition including anethole trithione or a derivative thereof of formula (I), sulfobutyl ether-beta-cyclodextrin and optionally a co-solvent, wherein the ratio of the sulfobutyl ether-beta-cyclodextrin to the compound of formula (I) ranges from 10 to 400, preferably from 57 to 200. Also, the use of the composition as a drug, namely for the treatment and/or the prevention of free oxygen radical-related diseases. Further, a kit-of-parts and/or a medical device including the composition. Lastly, a method for solubilizing a compound of formula (I) in an aqueous medium.

Abstract: A complex of Ag, Zn, Cu, Pt, Au, oxides, hydroxides and salts thereof; with a cyclodextrin of formula (I). Advantageously, the complex further includes an organic therapeutic agent, preferably an antibiotic agent. The complexation advantageously maintains the metal: organic therapeutic agent molar ratio. Even more advantageously, the complexation enhances the intrinsic aqueous solubility of the metal-organic therapeutic agent association. Also, compositions, pharmaceutical compositions and adequate formulations and uses thereof as well as devices including a complex of the invention. Lastly, a method for improving the aqueous solubility of a metal selected from Ag, Zn, Cu, Pt, Au, Ru, As, Sb, Bi, Ti, V, Ni, Hg, Pb, Co, oxides, hydroxides and salts thereof by providing a reaction mixture including the metal, an aqueous medium and a cyclodextrin of formula (I).

Abstract: A process for the preparation of cyclodextrin oligomers or polymers, whereby the cyclodextrin molecules are coupled to one another covalently via a spacer arm, based on a coupling reaction between an alkyne and an azide producing the formation of an aromatic heterocyclic bridge between the coupled units. Also described are the cyclodextrin oligomers or polymers that are obtained and their uses.

Abstract: The present invention relates to water-soluble, non-covalent complexes of a group of prostaglandin derivatives including latanoprost and monosubstituted, charged ?-cyclodextrins, as well as uses of these complexes in therapeutic compositions that are administered topically for treating intraocular hypertension and glaucoma.